Home Featured Page 218

Featured

Latest

Jackie Tileston: Nondual Mysticism, 5-MeO-DMT, and the Trouble with Psychedelic Art

FDA Approves NRx’s Preservative-Free Generic Ketamine, but Its Bid to Ban Rivals’ Products Remains Pending

Weekly Psychedelic Policy Briefing: Oct. 27, 2026

Pharma Moves In: Investors, Developers and Lilly’s Carole Ho at the Psychedelic Healthcare Forum

Mostly Supportive, Somewhat Divided: Stakeholders Respond to FDA’s Psychedelics Docket

Mydecine Innovations Group Engages JBN Partners, LLC for Marketing Services

Stephen Hurst Resigns from MindMed Board of Directors

Psychedelic Bulletin: Big Pharma’s Foray Into Psychedelics; Psilocybin Trial Makes Headlines;...

Cybin Announces Additional Adelia Milestone Achievement

PT282 – Rabbi Zac Kamenetz & The Rev. Hunt Priest –...

Levitee Labs Announces Medical Advisory Board

Red Light Holland Psilocybin Truffles, Sold in The Netherlands, Complete Second...

Entheon Biomedical Provides Update on DMT Human Trial and Announces Regulatory...

Field Trip Announces Intention to Make Applications on Behalf of Patients...

PharmaTher Announces Publication of Research Data for KETABET™

EDITOR PICKS

Jackie Tileston: Nondual Mysticism, 5-MeO-DMT, and the Trouble with Psychedelic Art

FDA Approves NRx’s Preservative-Free Generic Ketamine, but Its Bid to Ban...

Weekly Psychedelic Policy Briefing: Oct. 27, 2026

How to Get DMT: Obtaining the Spirit Molecule

Having Sex on DMT: What You Need to Know

DMT Pricing Guide

ABOUT US

PsyNews.com has a single-sector focus. We are a news platform dedicated to covering the psychedelic industry. This includes companies, startups, venture capital firms, investment banks, pharma, research, etc, anything associated with the new emerging industry and asset class. Many of the chemicals and compounds involved are LSD, psilocybin, DMT, ketamine, MDMA, ecstasy, ibogaine, analogs, derivatives, psychedelic mushrooms, fungi, psilocin, entheogens, empathogens, indocybin, magic truffles (psilocybin sclerotia), etc. They range from classical and standard to new and exotic. PsyNews.com will cover all psychedelic news in the psy industry, including current events, updates, and what’s happening everywhere in the sector in term of developments and investments. We will be tracking companies worth, valuation, ROI, financials, stock, revenue, IPO’s, and more. Along with medical, recreational, clinical trials, FDA, mindfulness, psy space, 5-HT2A receptor experiments, and so forth. Join us on an unforgettable journey to the center of the psychedelic industry.

Featured

Jackie Tileston: Nondual Mysticism, 5-MeO-DMT, and the Trouble with Psychedelic Art

FDA Approves NRx’s Preservative-Free Generic Ketamine, but Its Bid to Ban Rivals’ Products Remains Pending

Weekly Psychedelic Policy Briefing: Oct. 27, 2026

Pharma Moves In: Investors, Developers and Lilly’s Carole Ho at the Psychedelic Healthcare Forum

Mostly Supportive, Somewhat Divided: Stakeholders Respond to FDA’s Psychedelics Docket

Mydecine Innovations Group Engages JBN Partners, LLC for Marketing Services

Stephen Hurst Resigns from MindMed Board of Directors

Psychedelic Bulletin: Big Pharma’s Foray Into Psychedelics; Psilocybin Trial Makes Headlines;...

Cybin Announces Additional Adelia Milestone Achievement

PT282 – Rabbi Zac Kamenetz & The Rev. Hunt Priest –...

Levitee Labs Announces Medical Advisory Board

Red Light Holland Psilocybin Truffles, Sold in The Netherlands, Complete Second...

Entheon Biomedical Provides Update on DMT Human Trial and Announces Regulatory...

Field Trip Announces Intention to Make Applications on Behalf of Patients...

PharmaTher Announces Publication of Research Data for KETABET™

EDITOR PICKS

Jackie Tileston: Nondual Mysticism, 5-MeO-DMT, and the Trouble with Psychedelic Art

FDA Approves NRx’s Preservative-Free Generic Ketamine, but Its Bid to Ban...

Weekly Psychedelic Policy Briefing: Oct. 27, 2026

POPULAR POSTS

How to Get DMT: Obtaining the Spirit Molecule

Having Sex on DMT: What You Need to Know

DMT Pricing Guide

POPULAR CATEGORY